CymaBay Therapeutics, Inc.
Simbol: CBAY
NASDAQ
32.48
USDTržna cena danes
-32.9591
Razmerje P/E
0.0000
Razmerje PEG
3.73B
Kapaciteta MRK
- 0.00%
Donos DIV
CymaBay Therapeutics, Inc. (CBAY) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1283.24 | 394.3 | 135.5 | 186.5 | ||||||||||||
balance-sheet.row.short-term-investments | 708.35 | 187.7 | 115.2 | 60.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 35.01 | 9.5 | 2.6 | 4.6 | ||||||||||||
balance-sheet.row.total-current-assets | 1318.25 | 403.8 | 138.1 | 191.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.83 | 5.7 | 0.9 | 1.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 22.36 | 22.4 | 0 | 8.1 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 9.26 | 2.8 | 2.9 | 1.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 39.45 | 30.9 | 3.8 | 11.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.account-payables | 12.78 | 3.8 | 1.1 | 2.7 | ||||||||||||
balance-sheet.row.short-term-debt | 11.12 | 10 | 0.7 | 0.6 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 397.14 | 99.2 | 90.3 | 51 | ||||||||||||
Deferred Revenue Non Current | 3.3 | 1.1 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -203.34 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 58.31 | 21.3 | 13.7 | 15.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 405.76 | 105.6 | 90.3 | 51 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 6.43 | 5.3 | 0.7 | 1.3 | ||||||||||||
balance-sheet.row.total-liab | 526.66 | 142.4 | 105.7 | 69.4 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.06 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3718.63 | -978.2 | -872.9 | -766.9 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.11 | 0.1 | -0.3 | 0 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4549.72 | 1270.3 | 909.3 | 899.8 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1357.7 | - | - | - | ||||||||||||
Total Investments | 730.71 | 210.1 | 115.2 | 68.8 | ||||||||||||
balance-sheet.row.total-debt | 413.58 | 114.5 | 90.9 | 51.6 | ||||||||||||
balance-sheet.row.net-debt | -161.31 | -92 | 70.6 | -74.2 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -105.37 | -105.4 | -106 | -90 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.77 | -2.7 | 0 | 0.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 15.23 | 15.2 | 9.5 | 10 | ||||||||||||
cash-flows.row.change-in-working-capital | 5.63 | 5.6 | -2.3 | 6.4 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | 2.73 | 2.7 | -1.4 | 2.3 | ||||||||||||
cash-flows.row.other-working-capital | 2.9 | 2.9 | -0.9 | 4 | ||||||||||||
cash-flows.row.other-non-cash-items | 19.06 | 14 | 14 | 2.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -72.53 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.acquisitions-net | -2.11 | -7.9 | -0.9 | 0.6 | ||||||||||||
cash-flows.row.purchases-of-investments | -305.67 | -305.7 | -175 | -78.1 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 219.55 | 219.6 | 129.1 | 126.8 | ||||||||||||
cash-flows.row.other-investing-activites | 2.11 | 7.9 | 0.9 | -0.6 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -86.57 | -86.6 | -46 | 48.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -25 | -47.7 | ||||||||||||
cash-flows.row.common-stock-issued | 339.36 | 345.8 | -0.5 | 70.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -0.5 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -25 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 7.46 | 335.1 | 75.5 | 95.7 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 345.77 | 345.8 | 24.6 | 118.5 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 26.59 | -0.4 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 186.24 | 186.2 | -105.5 | 97.6 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 574.89 | 206.5 | 20.3 | 125.8 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 388.64 | 20.3 | 125.8 | 28.2 | ||||||||||||
cash-flows.row.operating-cash-flow | -72.53 | -72.5 | -84.1 | -69.4 | ||||||||||||
cash-flows.row.capital-expenditure | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.free-cash-flow | -72.98 | -73 | -84.2 | -69.5 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 31.07 | 31.1 | 0 | 0 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
income-statement-row.row.gross-profit | 30.39 | 30.4 | -0.7 | -0.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 80.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 51.95 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 132.7 | 132.1 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 132.75 | 132.8 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.interest-income | 13.49 | 13.5 | 2 | 0.2 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 3.18 | 0.7 | 2 | 0.9 | ||||||||||||
income-statement-row.row.ebitda-caps | -94.8 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -101.68 | -101.7 | -93.1 | -87.6 | ||||||||||||
income-statement-row.row.income-before-tax | -105.37 | -105.4 | -106 | -90 | ||||||||||||
income-statement-row.row.income-tax-expense | 11.99 | 0 | 12.9 | 2.6 | ||||||||||||
income-statement-row.row.net-income | -111.68 | -105.4 | -118.9 | -92.6 |
Pogosto zastavljeno vprašanje
Kaj je CymaBay Therapeutics, Inc. (CBAY) skupna sredstva?
CymaBay Therapeutics, Inc. (CBAY) skupna sredstva so 434686000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 57000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.978.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -0.644.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -3.594.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -3.272.
Kaj je CymaBay Therapeutics, Inc. (CBAY) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -105370000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 114494000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 132071000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 206535000.000.